The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Pharma giant Novartis comfortably beat market forecasts with its fourth-quarter results on Friday, with the Swiss firm ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...

Novartis said Friday that it expects core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range and ...

Novartis increased sales by 15 percent to USD 13.2 billion in the fourth quarter of 2024. Profit rose by 7 percent to USD 2.8 ...

Bank of America Securities analyst Graham Parry has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with ...

Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.